Recent weeks have seen soaring COVID-19 cases across China, pushing many people to various domestic health platforms in an attempt to purchase coveted antiviral medication and fever-reduction pills.
Many places across China are now facing a dramatic spike in COVID-19 infections. Due to the increasing number of patients with severe symptoms, market demand for drugs such as Paxlovid and Azvudine has soared.
Following China's loosening of pandemic control measures earlier this month, the number of cases across the country has soared, while demand for drugs and medical supplies such as antipyretics, antigen tests and oximeters has skyrocketed.
With the recent lifting of pandemic control policies in China, the number of infections has risen sharply. Chinese internet giant Tencent launched a "COVID-19 Pills Mutual Help Public Welfare Platform."
On the evening of December 13, Fosun Pharma, the exclusive commercial partner of Chinese COVID-19 oral drug Azvudine, confirmed that the pills can soon be prescribed through online medical platforms.
With the adjustment of COVID-19 prevention and control policies in many cities in China, in addition to a wave of panic buying of cold medicines, some food products have become unexpectedly popular recently, such as canned yellow peaches and electrolyte water.
On December 13, the online COVID-19 Clinic of a Chinese internet hospital under 111, Inc., a domestic digital healthcare platform, began to pre-sell Paxlovid (nirmatrelvir tablets; ritonavir tablets), an oral antiviral drug for COVID-19. However, shortly after the news was reported, the drug was quickly removed from online platforms.
Operators of China's digital "itinerary card," a smartphone function that has played a key role in authorities' pursuit of zero COVID, announced on December 12 that the service will officially go offline at 0:00 on December 13.
China's State Council issued a series of new pandemic control measures on December 7, relaxing restrictions on travel and boosting the search volume on domestic ticketing platforms.
The "false negative COVID results" of Lanzhou Nucleus Gene Huaxi pulled by the Shenzhen-based nucleic acid testing company and its actual controller Zhang Hezi from behind the scenes to the front and center.
With Hainan being a popular tourist destination in China, many domestic tourist platforms showed that orders of air tickets and hotels soared after the province adjusted its pandemic prevention and control measures.
The Omicron COVID-19 variant, which appears more transmissible but less pathogenic than earlier strains of the coronavirus, has caused a surge in demand for nucleic acid testing in China this year. However, false positives have frequently been reported.
Many local authorities in China have successively issued new pandemic prevention measures in the last two days, reducing the frequency of nucleic acid testing and advocating for more antigen tests. This has triggered an increase in demand among Chinese consumers for antigen test kits, and resources are now in short supply.
Recently, Chinese nucleic acid testing companies have been controversial and accused of making huge profits during the COVID-19 pandemic. Among them, a company called Nucleus Gene has aroused widespread public doubts.
William Li, the co-founder and CEO of Chinese electric vehicle firm NIO, offered insight regarding user experience, supply chains, production capacity, and recent progress of the firm's mobile phone business.
Foxconn, Apple's largest iPhone foundry, said on November 7 that it is working hard to resume full production at its Zhengzhou factory as soon as possible, and lowered its fourth-quarter performance forecast.
Foxconn, the Taiwan-based leading iPhone assembler, issued a statement at midday on October 26 saying that "reports of 20,000 people diagnosed with COVID-19 at the Zhengzhou Industrial Park, Henan Province" circulating online were "seriously false information."
In response to rumors that "Bianlifeng sees wave of store closures", the Chinese convenience store chain startup told the domestic media on August 16: "There is no tide of store closures. The stores affected by the pandemic are gradually resuming business."
MenuSifu, a point of sale (POS) software developer, on July 27 announced it had closed a $20 million Series B fundraising round, led by Challenjers Venture.
Major digital platforms offering daily services to Shanghai residents have also adopted measures to support the efforts, including Meituan Waimai and DiDi Global Inc.